Morphine Use in ST-Elevation Myocardial Infarction With Downstream P 2 Y 12 Receptor Blockers—Insight From Observational Study
Journal of Cardiovascular Pharmacology and Therapeutics · 01.01.2022 · 27
DOI: 10.1177/10742484221107793 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, online erschienen am 21.07.2022. Verfasst von Ariel Roguin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, 26736Hillel Yaffe Medical Center, Hadera, Haifa, Israel. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Aims: Morphine use for patients presenting with NSTE-ACS is associated with excess mortality. However, the role of morphine in STE-ACS is ill characterized. We have recently confirmed direct prothrombotic effect of morphine using murine models. We sought to explore whether morphine use in STE-ACS patients, used to be scheduled for downstream P 2 Y 12 blockers, is negatively associated with procedural and clinical outcomes.
Methods
A single-center, observational retrospective analysis enrolling 130 non-randomized stable patients sustaining STE-ACS as their first manifestation of coronary disease, who presented between December 2010 and June 2013. All were managed by early invasive approach. Of study patients, 55 were treated by morphine, and 75 were not. All were administered downstream P 2 Y 12 blockers according to an already abandoned local policy. Outcomes evaluated included TIMI grade flow, thrombus burden, ST-segment resolution, myocardial function by echocardiography, and cardiovascular death.
Results
Morphine administration was associated with a significantly higher incidence of impaired final TIMI grade flow (TIMI < 3, 40% vs 4%, P < .05), lower incidence of ST-segment resolution >70% (40.7% vs 76.5%, P < .05), and a higher incidence of moderate or severe systolic dysfunction (48.1% vs 29.1%, P < .05) compared with morphine naive patients. Interestingly, the overall mortality rate was higher in the morphine-treated group (18% vs 5.3%, P < .05). Conclusions and Relevance: Morphine administration combined with the downstream P 2 Y 12 blockers practice signify a group with a higher occurrence of impaired myocardial reperfusion and cardiovascular death despite established on-time primary angioplasty.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, 26736Hillel Yaffe Medical Center, Hadera, Haifa, Israel.
- Department of Clinical Biochemistry, 58884Hadassah Hebrew University Hospital, Jerusalem, Israel.
ORCID-Profile: Rami Abu Fanne
Zitieren
APA
Roguin, A., Kobo, O., Meisel, S. R., Maraga, E., Frimerman, A., Amsalem, N., Malka, R., Levi, Y., & Fanne, R. A. (2022). Morphine Use in ST-Elevation Myocardial Infarction With Downstream P 2 Y 12 Receptor Blockers—Insight From Observational Study. Journal of Cardiovascular Pharmacology and Therapeutics, 27. https://doi.org/10.1177/10742484221107793
Vancouver
Roguin A, Kobo O, Meisel SR, Maraga E, Frimerman A, Amsalem N, et al. Morphine Use in ST-Elevation Myocardial Infarction With Downstream P 2 Y 12 Receptor Blockers—Insight From Observational Study. Journal of Cardiovascular Pharmacology and Therapeutics. 2022;27. doi:10.1177/10742484221107793
BibTeX
@article{Roguin2022,
author = {Roguin, Ariel and Kobo, Ofer and Meisel, Simcha Ron and Maraga, Emad and Frimerman, Aaron and Amsalem, Naama and Malka, Rinat and Levi, Yaniv and Fanne, Rami Abu},
title = {Morphine Use in ST-Elevation Myocardial Infarction With Downstream P 2 Y 12 Receptor Blockers—Insight From Observational Study},
journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
year = {2022},
volume = {27},
doi = {10.1177/10742484221107793}
}
EUVIMED